METHOD FOR PREDICTION OF CLINICAL OUTCOME OF MUSCULO-INVASIVE BLADDER CANCER FOLLOWING COMBINATION THERAPY Russian patent published in 2015 - IPC G01N33/52 G01N33/53 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, specifically to oncology, and concerns the prediction of the clinical outcome of musculo-invasive bladder cancer. The method involves measuring the activity of 26S proteasomes and NF-kB and p50 amounts in the tumour tissue. If the 26S proteasome activity is more than 18-1,000 units/mg of protein, and if the NF-kB p65/p50 coefficient is more than 1.0, a low probability of the recurrence is predicted; if the 26S proteasome activity is less than 18-1,000 units/mg of protein, and if the NF-kB p65/p50 coefficient is less than 1.0, a high probability of the tumour recurrence is predicted. The invention can be used for detecting the progression of the disease in the form of the tumour recurrence following the transurethral resection of the bladder tumour and M-VAC polychemotherapy.

EFFECT: using the invention provides the higher accuracy and information value for predicting the clinical outcome of the bladder cancer.

2 ex, 2 dwg